Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy

Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy

BackgroundImmune checkpoint inhibitors (ICIs) have shown unprecedented clinical benefit in cancer immunotherapy and are rapidly transforming the practice of advanced lung cancer. However, resistance routinely develops in patients treated with ICIs. We conducted this retrospective study to provide an...

Full description

Bibliographic Details
Main Authors:	Jiebai Zhou, Xinyuan Lu, Haixing Zhu, Ning Ding, Yong Zhang, Xiaobo Xu, Lei Gao, Jian Zhou, Yuanlin Song, Jie Hu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Immunology
Subjects:	immune checkpoint inhibitor resistance advanced lung cancer plasma cytokines prognostic factor
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1089026/full

Similar Items

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021-11-01)

Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis
by: Dan Zou, et al.
Published: (2023-08-01)

Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
by: Xuebing Yan, et al.
Published: (2023-07-01)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
by: Lilong Zhang, et al.
Published: (2023-07-01)

A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors
by: Satu Tiainen, et al.
Published: (2023-12-01)

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
by: Fei Zheng, et al.
Published: (2023-07-01)

A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer
by: Yongchao Zhang, et al.
Published: (2023-01-01)

Fever of unknown origin associated with immune checkpoint inhibitors
by: Xu Tong, et al.
Published: (2024-03-01)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
by: Vera Petrova, et al.
Published: (2023-02-01)

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
by: Deirdre Kelly, et al.
Published: (2021-07-01)

Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study
by: Ruopeng Su, et al.
Published: (2023-05-01)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
by: Jie Zhao, et al.
Published: (2022-10-01)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
by: Jesper Geert Pedersen, et al.
Published: (2020-05-01)

Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors
by: Hao Sun, et al.
Published: (2022-11-01)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
by: Zhuochao Zhang, et al.
Published: (2023-05-01)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
by: Danming He, et al.
Published: (2023-10-01)

Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
by: Li Pang, et al.
Published: (2023-03-01)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
by: Daniel E. Meyers, et al.
Published: (2019-11-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
by: Ning Luo, et al.
Published: (2023-08-01)

Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors
by: Jiaxin Cao, et al.
Published: (2023-12-01)

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
by: Albert Jang, et al.
Published: (2023-12-01)

Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
by: Dalia Kaakour, et al.
Published: (2022-04-01)

Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
by: Xiaoyan Si, et al.
Published: (2023-07-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
by: Xin-Cheng Mao, et al.
Published: (2022-08-01)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
by: Xiaoling Gong, et al.
Published: (2022-11-01)

Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Pingping Mei, et al.
Published: (2023-11-01)

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
by: Lucile Pabst, et al.
Published: (2023-04-01)

Stratification of risk based on immune signatures and prediction of the efficacy of immune checkpoint inhibitors in prostate cancer
by: Yidan Sun, et al.
Published: (2023-11-01)

LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
by: Ken Arimura, et al.
Published: (2023-12-01)

Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors
by: YANG Wenwen, et al.
Published: (2022-05-01)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
by: Qian Zhang, et al.
Published: (2023-02-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
by: Carmen Portenkirchner, et al.
Published: (2021-04-01)

Immune Checkpoint Inhibitors in Prostate Cancer
by: Shobi Venkatachalam, et al.
Published: (2021-05-01)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
by: Xiaoxiao Guo, et al.
Published: (2020-02-01)

RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era
by: Shira Sagie, et al.
Published: (2022-06-01)

A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer
by: Zhuo Chen, et al.
Published: (2024-06-01)

Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
by: Qian Qin, et al.
Published: (2022-08-01)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
by: Wenxian Wang, et al.
Published: (2022-12-01)

A prognostic NAD+ metabolism-related gene signature for predicting response to immune checkpoint inhibitor in glioma
by: Cheng Jiang, et al.
Published: (2023-02-01)